US2014328909A1PendingUtilityA1

Krill oil and reacted astaxanthin composition and associated method

77
Assignee: US NUTRACEUTICALS LLC DBA VALENSA INTPriority: Jul 23, 2009Filed: Jul 21, 2014Published: Nov 6, 2014
Est. expiryJul 23, 2029(~3 yrs left)· nominal 20-yr term from priority
Inventors:John A. MinatelliW. Stephen HillRudi E. Moerck
A23V 2002/00A61K 31/122A23L 1/3006A61K 31/683A61K 35/612A61K 9/4808A23L 33/12A23L 33/115A23L 33/105A61K 31/047A61K 31/202
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating and alleviating joint pain includes administering a therapeutic amount of a composition comprising krill oil reacted with astaxanthin. A medicine delivery system for the method and composition includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S′-astaxanthin derived from Haematococcus pluvialis.

Claims

exact text as granted — not AI-modified
1 . A method of treating and alleviating joint pain in humans by administering a therapeutic amount of a dietary supplement composition comprising a reaction product of krill oil and astaxanthin, wherein the astaxanthin comprises S, S′-astaxanthin derived from  Haematococcus pluvialis.    
     
     
         2 . The method according to  claim 1 , wherein the krill oil comprises phospholipid bound and triglyceride bound EPA and DHA, the krill oil comprising 30% total phospholipids. 
     
     
         3 . The method according to  claim 1 , comprising administering 50 to 1,000 mg of krill oil. 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . The method according to  claim 1 , comprising administering the composition as a food product. 
     
     
         7 . The method according to  claim 1 , comprising administering the composition as a cosmetic applied to the skin. 
     
     
         8 . The method according to  claim 1 , comprising reacting the krill oil and astaxanthin after ingesting an outer capsule containing the krill oil and an inner capsule containing the astaxanthin. 
     
     
         9 . The method according to  claim 1 , comprising administering low molecular weight polymers of hyaluronic acid or sodium hyaluronate (hyaluronan). 
     
     
         10 . A method of treating and alleviating joint pain in humans by administering a therapeutic amount of a dietary supplement composition comprising a reaction product of krill oil and astaxanthin mono and diesters derived from  Haematococcus pluvialis , wherein the astaxanthin mono and diesters derived from  Haematoccus pluvialis  are 0.1 to 2.7 percent by weight of the krill oil. 
     
     
         11 . The method according to  claim 10 , wherein the krill oil comprises phospholipid bound and triglyceride bound EPA and DHA, the krill oil comprising 30% total phospholipids. 
     
     
         12 . The method according to  claim 10 , comprising administering 50 to 1000 mg of krill oil. 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . The method according to  claim 10 , comprising administering the composition as a food product. 
     
     
         16 . The method according to  claim 10 , comprising administering the composition as a cosmetic applied to the skin. 
     
     
         17 . The method according to  claim 10 , comprising forming the reaction product by reacting the krill oil and astaxanthin after ingesting an outer capsule containing the krill oil and an inner capsule containing the astaxanthin. 
     
     
         18 . The method according to  claim 10 , wherein the krill oil is derived from  Euphasia  spp. comprising Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids in the form of traicylglycerides and phospholipids. 
     
     
         19 . The method according to  claim 18 , wherein the krill oil includes at least 10% EPA and 5% DHA. 
     
     
         20 . The method according to  claim 10 , wherein the astaxanthin is derived from  Haematococcus pluvialis  algae oleoresin or beadlet. 
     
     
         21 . The method according to  claim 10 , wherein composition includes an n-3 (omega-3) fatty acid rich oil derived from flax seed oil, perilla seed oil, or chic seed oil, wherein the n-3 fatty acid comprises alpha-linolenic acid. 
     
     
         22 . The method according to  claim 10 , comprising administering low molecular weight polymers of hyaluronic acid or sodium hyaluronate (hyaluronan). 
     
     
         23 . The method according to  claim 9 , comprising administering low molecular weight polymers of hyaluronic acid or sodium hyaluronate (hyaluronan) having a molecular weight of less than 230 kilodaltons (kDa). 
     
     
         24 . The method according to  claim 23 , comprising administering low molecular weight polymers of hyaluronic acid or sodium hyaluronate (hyaluronan) having a molecular weight of between 0.5 to 100 kilodaltons (kDa). 
     
     
         25 . The method according to  claim 22 , comprising administering low molecular weight polymers of hyaluronic acid or sodium hyaluronate (hyaluronan) having a molecular weight of less than 230 kilodaltons (kDa). 
     
     
         26 . The method according to  claim 25 , comprising administering low molecular weight polymers of hyaluronic acid or sodium hyaluronate (hyaluronan) having a molecular weight of between 0.5 to 100 kilodaltons (kDa).

Join the waitlist — get patent alerts

Track US2014328909A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.